38.86
-1.40 (-3.48%)
| Penutupan Terdahulu | 40.26 |
| Buka | 39.22 |
| Jumlah Dagangan | 733,263 |
| Purata Dagangan (3B) | 1,135,667 |
| Modal Pasaran | 2,772,881,152 |
| Harga / Buku (P/B) | 4.78 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| EPS Cair (TTM) | -3.00 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.18% |
| Nisbah Semasa (MRQ) | 27.68 |
| Aliran Tunai Operasi (OCF TTM) | -155.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -97.14 M |
| Pulangan Atas Aset (ROA TTM) | -23.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -39.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Vera Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.60 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.97% |
| % Dimiliki oleh Institusi | 112.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sofinnova Investments, Inc. | 31 Dec 2025 | 2,793,987 |
| Integral Health Asset Management, Llc | 31 Dec 2025 | 1,800,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 110.00 (HC Wainwright & Co., 183.07%) | Beli |
| Median | 99.00 (154.76%) | |
| Rendah | 88.00 (Wolfe Research, 126.45%) | Beli |
| Purata | 99.00 (154.76%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 41.23 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wolfe Research | 11 Mar 2026 | 88.00 (126.45%) | Beli | 42.04 |
| HC Wainwright & Co. | 02 Mar 2026 | 110.00 (183.07%) | Beli | 40.42 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| WRIGHT-MITCHELL JANE | 40.73 | - | 42,403 | 1,727,074 |
| Jumlah Keseluruhan Kuantiti Bersih | 42,403 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 1,727,074 | |||
| Purata Pembelian Keseluruhan ($) | 40.73 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WRIGHT-MITCHELL JANE | Pegawai | 23 Mar 2026 | Diperolehi (+) | 42,403 | 40.73 | 1,727,074 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Feb 2026 | Pengumuman | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 28 Jan 2026 | Pengumuman | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer |
| 09 Jan 2026 | Pengumuman | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 08 Jan 2026 | Pengumuman | Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 07 Jan 2026 | Pengumuman | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |